InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
08 nov. 2018 08h05 HE
|
InCarda Therapeutics, Inc.
Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial...